secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055673
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024
--------------------------------------------------------------------------------

- Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).
- Cash, equivalents & securities $311.1M (Dec 2023: $205.2M); boosted by $189.8M gross equity offering in Feb 2024.
- Non-GAAP operating cash burn $58.7M in Q1 vs $74.8M YoY; full-year 2024 cash burn guided below $200M.
- Four ongoing clinical programs (SC291, SC262, UP421) across seven indications; initial data expected throughout 2024.
- R&D expenses $56.4M, down 16% from $67.2M, reflecting 2023 strategic repositioning and headcount reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/0000950170-24-055673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/sana-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer